Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by mjn797979on Jun 26, 2020 3:58pm

102 Views

Post# 31196954

RE:RE:If you read GUD's report, you also need to read GBT's report

Why not do a press release for Cresemba if its a drug they deem to be key?
I would have liked to have a seperate press release instead of it added to the financials release.
I think they can do a better job with guidance but maybe they don't care about retail investors like myself lol.

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?